<DOC>
	<DOCNO>NCT02027103</DOCNO>
	<brief_summary>Oral hypoglycemic agent , along dietary modification exercise encompass mainstay treatment early stage T2DM . Biguanides thiazolidinediones two major group hypoglycemic medication function via different pathway , mare effective short- long-term glucose control . These medication diminish delay long term micro- macrovascular complication associate T2DM although different rate . Excessive insulin resistance account sustain increase cardiovascular incident T2DM subject . Given share pathway insulin resistance/fetuin-A/OPG atherosclerosis formation , conceivable insulin sensitize anti-diabetes medication able modify successive CAD risk via direct indirect amelioration insulin resistance/fetuin-A/OPG . The present study therefore design investigate effect metformin pioglitazone monotherapy serum concentration fetuin-A OPG group Iranian adults newly diagnose T2DM .</brief_summary>
	<brief_title>Metformin Pioglitazone Effects Fetuin-A Osteoprotegrin Concentrations Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnose type 2 diabetes patient base American Diabetes Association criterion ( 2011 ) diagnosis diabetes Previous intake oral hypoglycemic agent treatment diabetes hyperglycemia associate condition Intake glucocorticoid past one year Major illness heart , lung , kidney , liver .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Fetuin-A</keyword>
	<keyword>OPG</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>